The following is from Beckers Hospital Review. As part of Project NextGen, HHS has awarded more than $1.4 billion in grants to support the development of the next generation of Covid-19 vaccines and technologies. Project NextGen is a $5 billion initiative led […]
The following is from MedPage, which is supported by the pharmaceutical industry. An FDA advisory committee on Thursday gave strong backing to use of a monoclonal antibody against respiratory syncytial virus (RSV) to prevent lower respiratory tract disease (LRTD) in
Dr. John Dye provides clarity amidst the Covid confusion and misinformation. He’s a top virologist for the military at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) where important biodefense work is performed.
Trump on Covid school closures in Chicago and Biden’s ‘egregious federal government overreach’ with vaccine mandates
January 5, 2022 Statement by Donald J. Trump, 45th President of the United States of America The Biden Administration’s response to COVID is getting worse every day. Joe Biden said, “there is no federal solution” to the pandemic, but he
Last summer, Florida became was one of the heaviest promoters of monoclonal antibody treatments (MAB) for its residents infected with Covid-19. By September, Florida was buying treatments directly from pharmaceutical manufacturers. But since then, the federal government’s Human and Health
A treatment for Covid-19 involving monoclonal antibodies produced by Eli Lilly is being halted nationwide: bamlanivimab and etesevimab as a combination therapy. Monoclonal antibodies are lab-made proteins that “mimic the immune system’s ability to fight off harmful pathogens such as
Virologist Dr. John Dye of the US Army Medical Research Institute of Infectious Diseases gives the government’s latest thinking on COVID-19, natural immunity, successful emerging treatments, and what lies ahead.
A summary of this week’s upcoming “Full Measure” interview with Dr. John Dye about natural immunity, therapies, and treatments for Covid-19.